2024

1. A Qualitative Tool to Guide in the Interpretation of the Numerical Rating Scale for Pruritus Intensity in Patients with Atopic Dermatitis

   Acta Dermato-Venereologica, Vol. 104

2. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

   AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

3. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)

   American Journal of Hematology

4. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

   Multiple Sclerosis and Related Disorders, Vol. 90

5. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

   Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

6. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis

   Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 10, pp. 2062-2074.e11

7. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

   Blood, Vol. 144, Núm. 6, pp. 646-656

8. GEMA-Na and MELD 3.0 severity scores to address sex disparities for accessing liver transplantation: a nationwide retrospective cohort study

   eClinicalMedicine, Vol. 74

9. Identification of patient-reported outcomes measures (PROMs) and patient-reported experiences measures (PREMs) in Gaucher disease in Spain

   Medicina Clinica, Vol. 163, Núm. 9, pp. 449-457

10. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

11. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

12. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

13. International consensus on post-transplantation diabetes mellitus

    Nephrology Dialysis Transplantation

14. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

15. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

    Blood

16. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice

    Journal of the European Academy of Dermatology and Venereology, Vol. 38, Núm. 9, pp. 1783-1790

17. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

18. Rat hepatitis E virus (Rocahepevirus ratti) in people living with HIV

    Emerging Microbes and Infections, Vol. 13, Núm. 1

19. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

20. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis

    European Journal of Clinical Investigation, Vol. 54, Núm. 2